Logo
x

Search category

Subscribe Now

All Posts by Date

Insights+ Key Biosimilars Events of May 2019

Insights+ Key Biosimilars Events of May 2019

  • June 4, 2019
Novartis Reports Results of Capmatinib in P-II GEOMETRY mono-1 Study for Non-Small Cell Lung Cancer with MET exon-14 Skipping Mutation #ASCO2019

Novartis Reports Results of Capmatinib in P-II GEOMETRY mono-1 Study for Non-Small Cell Lung Cancer with MET exon-14 Skipping Muta...

  • June 4, 2019
AstraZeneca and Merck Report Results of Lynparza (olaparib) in P-III SOLO3 Study for Platinum-Sensitive Relapsed Germline BRCA-mutated Advanced Ovarian Cancer #ASCO2019

AstraZeneca and Merck Report Results of Lynparza (olaparib) in P-III SOLO3 Study for Platinum-Sensitive Relapsed Germline BRCA-mut...

  • June 4, 2019
Merck's Zerbaxa (ceftolozane and tazobactam) Receives FDA's Approval for Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia in Adults

Merck's Zerbaxa (ceftolozane and tazobactam) Receives FDA's Approval for Hospital-Acquired and Ventilator-Associated Bacterial Pne...

  • June 4, 2019
Roche Reports Results of Xofluza (baloxavir marboxil) in P-III BLOCKSTONE Study for the Prevention of Influenza

Roche Reports Results of Xofluza (baloxavir marboxil) in P-III BLOCKSTONE Study for the Prevention of Influenza

  • June 4, 2019
Takeda Reports Results of Takhzyro (lanadelumab) in P-III HELP Study for the Prevention of Hereditary Angioedema Attacks

Takeda Reports Results of Takhzyro (lanadelumab) in P-III HELP Study for the Prevention of Hereditary Angioedema Attacks

  • June 4, 2019
Image

Stay Connected

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.